

## SUPPLEMENTAL INFORMATION

**Table S1: Baseline demographics**

	Placebo (n=136)	CZP 200 mg Q2W (n=138)	CZP 400 mg Q4W (n=135)
<b>Demographic characteristics</b>			
Age, years	47.3 ± 11.1	48.2 (12.3)	47.1 (10.8)
Sex, % female	58.1	53.6	54.1
Race, % white	97.1	97.8	98.5
Weight, kg	82.6 ± 19.9 <sup>††</sup>	85.8 ± 17.7	84.8 ± 18.7
BMI, kg/m <sup>2</sup>	29.2 ± 6.7 <sup>††</sup>	30.5 ± 6.2	29.6 ± 6.6
<b>Arthritis characteristics</b>			
Psoriatic arthritis duration, years	18.0 ± 12.3	17.3 ± 12.3	16.8 ± 13.4
CRP** (mg/L), median (min-max)	9.0 (0.2 – 131.0)	7.0 (0.2 – 238.0)	8.7 (0.1 – 87.0)
ESR (mm/h), median (min-max)	34.0 (6.0 – 125.0)	35.0 (5.0 – 125.0)	33.0 (4.0 – 120.0)
Tender joint count (0-68 joints)	19.9 ± 14.7	21.5 ± 15.3	19.6 ± 14.8
Swollen joint count (0-66 joints)	10.4 ± 7.6	11.0 ± 8.8	10.5 ± 7.5
HAQ-DI (range 0-3)	1.3 ± 0.7	1.3 ± 0.7	1.3 ± 0.6
Modified total Sharp score	24.4 ± 46.5	18.0 ± 30.6	22.8 ± 46.5
Erosion score	14.0 ± 27.0	10.3 ± 17.3	13.4 ± 25.2
Joint space narrowing score	10.4 ± 23.3	7.7 ± 14.5	9.4 ± 22.1
<b>Prior use of synthetic DMARDs, %</b>			
1	54.4	44.2	53.3
≥ 2	44.1	52.9	44.4
<b>Prior use of NSAIDs, %</b>			
	83.8	81.9	91.1
<b>Prior TNF inhibitor exposure, %</b>			
	19.1	22.5	17.0
<b>Concomitant MTX at baseline, %</b>			
	61.8	63.8	65.2

\* Except where indicated otherwise, values are the mean ± SD. There were no significant differences between treatment groups at baseline. BMI: Body mass index; CRP: C-reactive protein; CZP: Certolizumab pegol; DI: Disability index; DMARDs: Disease-modifying antirheumatic drugs; ESR: Erythrocyte sedimentation rate HAQ: Health Assessment Questionnaire; NSAIDs: Nonsteroidal antiinflammatory drugs; MTX: Methotrexate; Q2W: Every 2 weeks; Q4W: Every 4 weeks; TNF: Tumor necrosis factor

\*\* Normal range of CRP < 8.0 mg/L


†† n=135

**Table S2: Change from baseline in mTSS and mTSS nonprogressor rates by baseline risk factors**

Baseline risk factor	Treatment	Mean mTSS change from baseline	mTSS nonprogressor rate (%)
CRP ≤15 mg/L	Placebo (n=90)	0.12	92.2
	CZP (n=194)	0.03	96.9
CRP >15 mg/L	Placebo (n=46)	0.51	78.3
	CZP (n=79)	0.08*	96.2*
mTSS ≤ median (6)	Placebo (n=78)	0.06	97.4
	CZP (n=130)	0.04	98.4
mTSS > median (6)	Placebo (n=58)	0.54	74.1
	CZP (n=143)	0.08*	95.1*

\* p<0.05; CRP: C-reactive protein; CZP: Certolizumab pegol; mTSS: modified total Sharp score. mTSS nonprogressor defined as mean mTSS change from baseline ≤0.5. Median mTSS change from baseline imputation was used in patients with <2 analyzable mTSS scores.

**Figure S1: Patient disposition and availability of radiographs**



BL: Baseline; CZP: Certolizumab pegol; LD: Loading dose; mTSS: modified total Sharp score; PBO: Placebo; Q2W: Every 2 weeks; Q4W: Every 4 weeks; Wk: Week.